Edition:
United States

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

8.22USD
3:59pm EST
Change (% chg)

$-0.40 (-4.64%)
Prev Close
$8.62
Open
$8.46
Day's High
$8.70
Day's Low
$8.17
Volume
148,712
Avg. Vol
84,232
52-wk High
$9.70
52-wk Low
$3.88

Latest Key Developments (Source: Significant Developments)

Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK
Monday, 8 Jan 2018 08:21am EST 

Jan 8 (Reuters) - Adaptimmune Therapeutics Plc ::ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING.ADAPTIMMUNE THERAPEUTICS - AGREEMENT IS FOR TERM OF 5 YEARS WITH EARLIER TERMINATION AVAILABLE TO BOTH PARTIES ON PROVISION OF 12 MONTHS' NOTICE.ADAPTIMMUNE THERAPEUTICS PLC - AGREEMENT WILL ENABLE CO TO HAVE ITS OWN DEDICATED VECTOR MANUFACTURING SPACE IN UK.ADAPTIMMUNE - AGREEMENT TO ENSURE VECTOR SUPPLY PRODUCTION BEYOND 2020 FOR ONGOING STUDIES WITH 3 SPEAR T-CELL THERAPIES, MAGE-A4, MAGE-A10 AND AFP.  Full Article

Adaptimmune Announces Positive Safety Data From Pilot Studies With MAGE-A10 SPEAR T-Cells
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Adaptimmune Therapeutics Plc :::ADAPTIMMUNE ANNOUNCES POSITIVE SAFETY DATA FROM PILOT STUDIES WITH MAGE-A10 SPEAR T-CELLS AND FIRST PATIENT TO RECEIVE 1 BILLION TARGET CELL DOSE.ADAPTIMMUNE THERAPEUTICS PLC - NO EVIDENCE OF TOXICITY RELATED TO OFF-TARGET BINDING OR ALLOREACTIVITY HAS BEEN OBSERVED.ADAPTIMMUNE - IN NSCLC STUDY, THERE HAS BEEN ONE SERIOUS ADVERSE EVENT OF CYTOKINE RELEASE SYNDROME, A GRADE 4 EVENT THAT RESOLVED WITH TREATMENT.ADAPTIMMUNE THERAPEUTICS PLC - ADVERSE EVENT OF CYTOKINE RELEASE SYNDROME IN NSCLC STUDY LED TO COHORT 1 EXPANSION FROM 3 TO 6 PATIENTS.  Full Article

Adaptimmune Therapeutics Q3 loss per share $0.00
Thursday, 2 Nov 2017 07:30am EDT 

Nov 2 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune reports third quarter 2017 financial results and business updates.Q3 revenue $27.2 million versus $2.4 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.00.Adaptimmune- existing cash, cash equivalents, securities, income from GSK on transition of NY-ESO program to fund operating plan through to early 2020​.  Full Article

Matrix Capital reports 12.9 pct passive stake in Adaptimmune Therapeutics
Monday, 11 Sep 2017 08:31am EDT 

Sept 11 (Reuters) - Matrix Capital Management Co Lp::Matrix Capital Management Company Lp reports 12.9 percent passive stake in Adaptimmune Therapeutics Plc as of August 31, 2017 - SEC filing.  Full Article

GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO
Thursday, 7 Sep 2017 07:30am EDT 

Sept 7 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune Therapeutics Plc - ‍GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO​.Adaptimmune Therapeutics Plc - ‍Adaptimmune will receive up to £48 million ($61 million) from GSK over course of transition period​.Adaptimmune Therapeutics Plc - ‍anticipate transition of NY-ESO to GSK to be completed over coming months​.  Full Article

Adaptimmune reports Q2 revenue $3.5 million
Thursday, 3 Aug 2017 07:30am EDT 

Aug 3 (Reuters) - Adaptimmune Therapeutics Plc ::Adaptimmune reports second quarter 2017 financial results.Q2 revenue $3.5 million.Q2 revenue view $5.4 million -- Thomson Reuters I/B/E/S.Q2 loss per share $0.04.Q2 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.  Full Article

Biolife Solutions executes supply agreement with Adaptimmune for Cryostor
Wednesday, 14 Jun 2017 06:00am EDT 

June 14 (Reuters) - Biolife Solutions Inc :Biolife solutions executes supply agreement with adaptimmune for cryostor® use in spear t-cell platform.Biolife solutions inc - that it has entered into a supply agreement with nasdaq-listed adaptimmune therapeutics plc.  Full Article

Adaptimmune announces data from NY-ESO study in Synovial Sarcoma at ASCO annual meeting
Monday, 5 Jun 2017 09:50am EDT 

June 5 (Reuters) - Adaptimmune Therapeutics PLC ::Adaptimmune announces an oral presentation on data from NY-ESO study in Synovial Sarcoma and four trials in progress posters at the American Society Of Clinical Oncology (ASCO) annual meeting.From ongoing NY-ESO Synovial Sarcoma study, NY-ESO continues to be generally well-tolerated.From ongoing NY-ESO Synovial Sarcoma study, initial anti-tumor activity observed in all ongoing cohorts.  Full Article

Adaptimmune Q1 loss per share $0.05
Wednesday, 10 May 2017 07:30am EDT 

May 10 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune reports first quarter 2017 financial results.Q1 revenue $2.9 million.Q1 revenue view $4.9 million -- Thomson Reuters I/B/E/S.Adaptimmune therapeutics plc - offerings in march and april raised net proceeds of $103.2 million; operations funded through to late 2019.Q1 loss per share $0.05.  Full Article

Adaptimmune Therapeutics proposes public offering of American Depositary Shares
Tuesday, 21 Mar 2017 04:55pm EDT 

Adaptimmune Therapeutics Plc : Adaptimmune Therapeutics Plc proposes public offering of American Depositary Shares .Adaptimmune Therapeutics Plc - net proceeds from offering to be used to advance co's pipeline of Spear T-cell candidates through clinical trials.  Full Article

BRIEF-Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK

* ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING